Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.

NCT01399619 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01399619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01399619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
June 30, 2014
Enrollment
310 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic